When used to prevent thrombotic events after an acute coronary syndrome, the newer oral anticoagulants (for example, apixaban, dabigatran, and rivaroxaban) are associated with increased rates of major bleeding that offset their antithrombotic benefit, according to anArchives of Internal Medicine meta-analysis.
Researchers examined seven randomized controlled trials comprising over 30,000 patients who were hospitalized with ACS and received antiplatelet therapy. Compared with placebo recipients, those on new-generation oral anticoagulants had "a dramatic increase in major bleeding events." Significant (but moderate) reductions in the risks for stent thrombosis and other ischemic events were seen, but there was no significant effect on overall mortality.
An editorialist concludes that routine use of these drugs in patients with ACS "is unwarranted."
Acute coronary syndrome is a term used for any condition brought on by sudden, reduced blood flow to the heart.
No comments:
Post a Comment